Q1 Earnings Forecast for LRMR Issued By HC Wainwright

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for Larimar Therapeutics in a research report issued to clients and investors on Tuesday, March 25th. HC Wainwright analyst E. White anticipates that the company will earn ($0.43) per share for the quarter. HC Wainwright has a "Buy" rating and a $16.00 price objective on the stock. The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Larimar Therapeutics' Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.54) EPS and FY2027 earnings at ($1.57) EPS.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last issued its earnings results on Monday, March 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.16).

Other analysts also recently issued research reports about the stock. Robert W. Baird reduced their target price on shares of Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating for the company in a report on Tuesday, March 25th. Guggenheim restated a "buy" rating and set a $26.00 target price on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. Finally, Truist Financial began coverage on shares of Larimar Therapeutics in a research report on Wednesday, January 29th. They set a "buy" rating and a $18.00 price objective for the company. Eleven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $20.22.

Remove Ads

Larimar Therapeutics Trading Down 2.1 %

Shares of LRMR traded down $0.05 during mid-day trading on Wednesday, reaching $2.35. The company's stock had a trading volume of 986,346 shares, compared to its average volume of 645,138. The stock has a market cap of $149.95 million, a P/E ratio of -2.04 and a beta of 0.99. Larimar Therapeutics has a 1-year low of $2.19 and a 1-year high of $11.20. The business has a 50-day simple moving average of $3.08 and a two-hundred day simple moving average of $5.10.

Institutional Trading of Larimar Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of LRMR. BNP Paribas Financial Markets bought a new stake in Larimar Therapeutics during the 4th quarter valued at $25,000. Algert Global LLC bought a new position in Larimar Therapeutics in the 4th quarter worth about $47,000. China Universal Asset Management Co. Ltd. purchased a new position in Larimar Therapeutics during the 4th quarter valued at about $52,000. Graham Capital Management L.P. purchased a new stake in shares of Larimar Therapeutics in the fourth quarter worth about $54,000. Finally, ProShare Advisors LLC purchased a new position in Larimar Therapeutics during the fourth quarter valued at approximately $58,000. Institutional investors own 91.92% of the company's stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.